Tuesday, March 17, 2026

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

U.S. Hits Chinese Battery Supplier With Shocking 712% Tariff

The U.S. plans a 712% duty on Huizhou Kaixin, boosting South Korean battery firms while raising concerns over production costs.

Tag: Kang Young-joo

No posts to display

Top News

- Our Sponsors Ad -

Follow us